Bausch & Lomb: Activist Investor Loeb Discloses a 9% Passive Stake
-
Font Size:
-
Print
- TweetThis
Bausch & Lomb is currently in a definitive merger agreement with Warburg Pincus to be acquired for $65 per share. Rival Advanced Medical Optics Inc. (NYSE: EYE) recently withdrew its $75 per share offer for Bausch & Lomb.
The 13G filing indicates a passive stake, but Loeb is considered an activist investor.
So what does Loeb have up his sleeve for Bausch & Lomb? If Loeb had immediate intentions to rattle management he would have had to file a 13D, so the 13G indicates Loeb prefers to take a 'wait and see' approach.
BOL 1-yr chart
One thought is that Loeb could be letting another firm take the lead. In the past, Stevie Cohen's SAC Capital filed a 13D on Bausch & Lomb. Loeb could be giving the Wall Street icon first dibs to grill management on its dumb decision to pursue a $65 deal with a private equity firm when a $75 deal was on the table. Cohen cut his stake in BOL below 5% in July and held less than 1 million shares as of July 10, 2007, but it is conceivable that Cohen is still involved with the stock given its recent pullback. Other firms could also be involved.
Related Articles
|

























